Established and Emerging Therapies for Acute Myeloid Leukaemia

 

The aim of this evaluation form is to gain your feedback, in order to maintain high educational standards and provide a reference for continuous improvement. Please indicate which rating reflects your answer.

Questions marked with are required.

1. . Did this E-Learning module provide an update on biological and clinical heterogeneity of acute myeloid leukaemia (AML)? (1: no, not at all; 5: yes, absolutely) *

2. . Did this E-Learning module underline importance of heterogeneity for risk stratification and treatment approach in patients with AML? (1: no, not at all; 5: yes, absolutely) *

3. . Did this E-Learning module provide an update on evidence base for already established treatments for AML? (1: no, not at all; 5: yes, absolutely) *

4. Please, provide your overall rating of the quality of the education offered by this E-Learning module. (1-poor; 5-excellent)

5. How would you rate the interactivity level offered in the E-Learning material? (1-poor; 5-excellent)

6. Was the information useful and relevant to your work and practice? (1-not at all; 5-absolutely)

7. Do you feel that the information presented was well balanced and supported by adequate evidence? (1-not at all; 5-absolutely)

8. Do you think that the scientific content of this E-learning activity contains any commercial material?

9. If you answered YES, please motivate your choice in the box below:

10. If you would like to add your personal comments or make suggestion to improve future ESMO E-Learning material, please write in the box below: